(Q47701435)
Statements
1 reference
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer (English)
1 reference
I Lang
1 reference
M J Inbar
1 reference
Z Kahán
1 reference
R Greil
1 reference
S Beslija
1 reference
S M Stemmer
1 reference
B Kaufman
1 reference
Z Zvirbule
1 reference
G G Steger
1 reference
D Messinger
1 reference
T Brodowicz
1 reference
C Zielinski
1 reference
26 May 2012
1 reference
48
1 reference
17
1 reference
3140-3149
1 reference